Article

Intraoperative radiation therapy for recurrent head-and-neck cancer: The UCSF experience

Stanford University, Palo Alto, California, United States
International Journal of Radiation OncologyBiologyPhysics (Impact Factor: 4.18). 02/2007; 67(1):122-9. DOI: 10.1016/j.ijrobp.2006.08.038
Source: PubMed

ABSTRACT To review a single-institutional experience with the use of intraoperative radiation therapy (IORT) for recurrent head-and-neck cancer.
Between 1991 and 2004, 137 patients were treated with gross total resection and IORT for recurrence or persistence of locoregional cancer of the head and neck. One hundred and thirteen patients (83%) had previously received external beam radiation as a component of definitive therapy. Ninety-four patients (69%) had squamous cell histology. Final surgical margins were microscopically positive in 56 patients (41%). IORT was delivered using either a modified linear accelerator or a mobile electron unit and was administered as a single fraction to a median dose of 15 Gy (range, 10-18 Gy). Median follow-up among surviving patients was 41 months (range, 3-122 months).
The 1-year, 2-year, and 3-year estimates of in-field control after salvage surgery and IORT were 70%, 64%, and 61%, respectively. Positive margins at the time of IORT predicted for in-field failure (p = 0.001). The 3-year rates of locoregional control, distant metastasis-free survival, and overall survival were 51%, 46%, and 36%, respectively. There were no perioperative fatalities. Complications included wound infection (4 patients), orocutaneous fistula (2 patients), flap necrosis (1 patient), trismus (1 patient), and neuropathy (1 patient).
Intraoperative RT results in effective disease control with acceptable toxicity and should be considered for selected patients with recurrent or persistent cancers of the head and neck.

0 Followers
 · 
112 Views
 · 
0 Downloads
  • Source
    • "In primary and recurrent retroperitoneal sarcomas , patients were less likely to experience relapse inside the IOERT field after undergoing R1-resection than after R2-resection (23.5% vs. 75%) [31]. In recurrent head-and-neck cancer, positive margins predicted in-field failure with 3-year local control rates of 82% for patients with free margins vs. 48% for positive margins [32]. Survival outcomes are influenced by multiple factors (distant and local status, complications and toxicity, comorbidity, second malignancies, study design, follow-up, etc.). "
    [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the influence of equivalent dose (EQD2) in clinical outcomes of patients with isolated locally recurrent tumors (ILRT), treated with salvage surgery and intra-operative electron beam radiation therapy (IOERT). We retrospectively reviewed 128 patients with non-metastatic ILRT of different tissues (soft tissue sarcomas, head and neck, uterine, and colorectal). Patients had received salvage surgery (R0/R1/R2) and IOERT. Previously not irradiated patients had received additional external beam radiation therapy (EBRT). IOERT was delivered at a median dose of 15Gy (range, 5-25Gy). Seventy-five patients (60.9%) received additional EBRT of 46Gy. Median EQD2 of salvage program was 62Gy and median EQD2 of exclusive IORT was 31.2Gy. Median follow-up was 19.2months (range: 1.3-220). Thirty-one patients (24.2%) developed severe (grade 3-5) complications. New locoregional recurrence was documented in 86 (67.2%) of the 123 cases. Five-year rates were 31% for locoregional control, 57% for distant metastasis-free and 31% for overall survival. On multivariate analysis, R0-1 vs. R2 resection (HR 2.2, 95 CI: 1.2-4.1) was statistically significant for locoregional recurrence and EQD2 ⩾62Gy for survival (HR 2.2, 95 CI: 1.1-4.1). Surgical radicality (gross macroscopic resection) and radiation dose (EQD2 ⩾62Gy in radiation salvage program) are the dominant prognostic factors beside ILRT histology. Modest rates of long-term disease control are expected when both factors are fulfilled. Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.
    Radiotherapy and Oncology 07/2015; DOI:10.1016/j.radonc.2015.07.009 · 4.86 Impact Factor
  • Source
    • "Recently, Chen et al reported the UCSF experience with 137 pts treated for recurrent head and neck cancer. Their 3-year in-field control rate and overall survival rate were 67% and 36%, respectively [11]. In another study, Pinheiro and colleagues reported their results for 44 patients treated at Mayo clinic. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study is to review our experience with the use of IORT for patients with advanced cervical metastasis. Between August 1982 and July 2007, 231 patients underwent neck dissections as part of initial therapy or as salvage treatment for advanced cervical node metastases resulting from head and neck malignancies. IORT was administered as a single fraction to a dose of 15 Gy or 20 Gy in most pts. The majority was treated with 5 MeV electrons (112 pts, 50.5%). 1, 3, and 5 years overall survival (OS) after surgery + IORT was 58%, 34%, and 26%, respectively. Recurrence-free survival (RFS) at 1, 3, and 5 years was 66%, 55%, and 49%, respectively. Disease recurrence was documented in 83 (42.8%) pts. The majority of recurrences were regional (38 pts), as compared to local recurrence in 20 pts and distant failures in 25 pts. There were no perioperative fatalities. IORT results in effective local disease control at acceptable levels of toxicity. Our results support the initiation of a phase III trial comparing outcomes for patients with cervical metastasis treated with or without IORT.
    Radiation Oncology 06/2011; 6:72. DOI:10.1186/1748-717X-6-72 · 2.36 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The mechanisms involved, and possible treatment targets, in orofacial pain due to cancer are poorly understood. The aim of the first of this two-part series is to review the involved pathophysiological mechanisms and explore their possible roles in the orofacial region. However, there is a lack of relevant research in the trigeminal region, and we have therefore applied data accumulated from experiments on cancer pain mechanisms in rodent spinal models. In the second part, we review the clinical presentation of cancer-associated orofacial pain at various stages: initial diagnosis, during therapy (chemo-, radiotherapy, surgery), and in the post-therapy period. In the present article, we provide a brief outline of trigeminal functional neuro-anatomy and pain-modulatory pathways. Tissue destruction by invasive tumors (or metastases) induces inflammation and nerve damage, with attendant acute pain. In some cases, chronic pain, involving inflammatory and neuropathic mechanisms, may ensue. Distant, painful effects of tumors include paraneoplastic neuropathic syndromes and effects secondary to the release of factors by the tumor (growth factors, cytokines, and enzymes). Additionally, pain is frequent in cancer management protocols (surgery, chemotherapy, and radiotherapy). Understanding the mechanisms involved in cancer-related orofacial pain will enhance patient management.
    Journal of Dental Research 07/2007; 86(6):491-505. DOI:10.1177/154405910708600604 · 4.14 Impact Factor
Show more

Preview

Download
0 Downloads
Available from